Last reviewed · How we verify
CP- 690,550 and Cyclosporine
CP- 690,550 and Cyclosporine is a Small molecule drug developed by Pfizer. It is currently in Phase 1 development.
At a glance
| Generic name | CP- 690,550 and Cyclosporine |
|---|---|
| Sponsor | Pfizer |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study Of JAK3 Inhibitor For The Prevention Of Acute Rejection In Kidney Transplant Patients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CP- 690,550 and Cyclosporine CI brief — competitive landscape report
- CP- 690,550 and Cyclosporine updates RSS · CI watch RSS
- Pfizer portfolio CI
Frequently asked questions about CP- 690,550 and Cyclosporine
What is CP- 690,550 and Cyclosporine?
CP- 690,550 and Cyclosporine is a Small molecule drug developed by Pfizer.
Who makes CP- 690,550 and Cyclosporine?
CP- 690,550 and Cyclosporine is developed by Pfizer (see full Pfizer pipeline at /company/pfizer).
What development phase is CP- 690,550 and Cyclosporine in?
CP- 690,550 and Cyclosporine is in Phase 1.
Related
- Manufacturer: Pfizer — full pipeline
- Compare: CP- 690,550 and Cyclosporine vs similar drugs
- Pricing: CP- 690,550 and Cyclosporine cost, discount & access